靶向肝炎D.

StephenW

Semin Liver Dis. 2018 Feb;38(1):66-72. doi: 10.1055/s-0037-1621711. Epub  2018 Feb 22.
Targeting Hepatitis D.Rizzetto M1.
Author information
1Division of Gastroenterology, University of Torino, Torino, Italy.

AbstractNew therapeutic strategies to treat chronic hepatitis D are directed to deprive the hepatitis D virus (HDV) of functions necessary to complete its life cycle that are provided by the hepatitis B virus (HBV) and by the host. Current options are (1) the block by the synthetic peptide Myrcludex B of HBV surface antigen (HBsAg) entry into cells through the inhibition of the sodium taurocholate cotransporting receptor; (2) the inhibition with lonafarnib of the farnesylation of the large HD antigen, required for virion assembly; (3) the presumed reduction by the nucleic acid polymer REP 2139 of the release of the HBsAg and subviral HBV particles necessary for HD virion morphogenesis. Lonafarnib and Myrcludex in monotherapy reduced serum HDV-RNA but did not reduce the HBsAg and HD viremia rebounded after therapy; they may provide additional efficacy to pegylated interferon alpha (Peg IFN-α) therapy. Treatment with REP-2139 in combination with Peg IFN-α induced a sustained clearance both of the HDV-RNA and HBsAg in 5 of 12 patients, providing the best interim results so far obtained in the therapy of chronic hepatitis D.


PMID:29471567DOI:10.1055/s-0037-1621711

StephenW

Semin Liver Dis。 2018年2月; 38（1）：66-72。 doi：10.1055 / s-0037-1621711。电子邮件2018年2月22日。
靶向肝炎D.
Rizzetto M1。
作者信息

1
    意大利都灵托里诺大学消化内科。

抽象

治疗慢性丁型肝炎的新治疗策略旨在剥夺由乙型肝炎病毒（HBV）和宿主提供的完成其生命周期所必需的功能的丁型肝炎病毒（HDV）。目前的选择是（1）HBV表面抗原（HBsAg）的合成肽Myrcludex B通过抑制牛磺胆酸钠共转运受体进入细胞; （2）利纳法尼抑制病毒体组装所需的大HD抗原的法尼基化; （3）假定核酸聚合物REP 2139减少了HD病毒体形态发生所必需的HBsAg和亚病毒颗粒的释放。 Lonafarnib和Myrcludex单药治疗可降低血清HDV-RNA，但不能降低治疗后HBsAg和HD病毒血症反弹;它们可以为聚乙二醇化干扰素α（Peg IFN-α）治疗提供额外的功效。 REP-2139联合Peg IFN-α治疗12位患者中5位能够持续清除HDV-RNA和HBsAg，提供迄今在慢性乙型肝炎治疗中获得的最佳中期结果。

结论：
    29471567
DOI：
    10.1055 / S-0037-1621711